Background: Type 2 diabetes mellitus (DM) and metabolic syndrome are associated with high risk of cardiovascular disease (CVD) and depression. Although lifestyle modifications including regular exercise and weight control are recommended as a primary approach to glycemic control and CVD risk reduction for people with DM and/or metabolic syndrome, little is known concerning the effects of CVD risk reduction interventions using psychobehavioral strategies in this population. Objective: This pilot study investigated the effects of a 16-week CVD risk reduction intervention in Korean adults with type 2 DM and metabolic syndrome. Methods: A prospective, pretest and posttest, controlled, quasi-experimental design enrolled a convenience sample of 43 Korean adults with type 2 DM and metabolic syndrome at a university hospital. The adults in the intervention group participated in a 16-week CVD risk reduction intervention consisting of 150 minutes of regular exercise per week; 200-to 300-kcal reduced daily diet for weight control; one-on-one psychobehavioral counseling based on constructs from the Transtheoretical Model such as processes of change, self-efficacy, and decisional balance; and telephone coaching for behavioral modification. Participants in the control group received a booklet with basic diabetic education as part of their routine care. Repeated-measures analysis of variance was used for analyzing the effects of the CVD risk reduction intervention on cardiometabolic risk factors including the UK Prospective Diabetes Study score for 10-year CVD risk, glycated hemoglobin (HbA 1c ), and depression. Results: The intervention group showed significant reductions (P G .05) at 16 weeks, compared with the control group on the UK Prospective Diabetes Study fatal risk scale (j1.73% vs j0.04%), triglycerides (j38.5 vs j15.1 mg/dL), fasting plasma glucose (j29.24 vs +1.77 mg/dL), HbA 1c (j0.37% vs +0.17%), and depression (score, j3.24 vs 1.40) measurements. Conclusions: This pilot study yielded evidence for the beneficial impact of the CVD risk reduction intervention for Korean adults with type 2 DM and metabolic syndrome on improved glycemic control, reduced CVD risk, and depression.
D iabetes mellitus (DM) is increasing worldwide.
The global prevalence of diabetes for all age groups internationally was estimated to be 2.8% in 2000 and is predicted to be 4.4% by 2030. 1 Diabetes mellitus is also increasing in Korea due to behaviors such as high-lipid diets and sedentary lifestyles. The prevalence rates of diabetes and prediabetes among adults 30 years or older in the 2008 Korea National Health and Nutrition Examination Survey were 10.7% and 21.7%, respectively. 2 Aspects of diabetes including insulin resistance and impaired glucose tolerance are well-established risk factors for cardiovascular disease (CVD). 3 Most patients with diabetes have serious diabetes-related complications including macrovascular and/or microvascular complications. Patients with diabetes are at a 2-to 4-fold greater risk of CVD than people without diabetes and are at high risk for cardiovascular mortality. 4, 5 In addition, CVD as the major cause of death accounts for 52% of deaths in those with type 2 DM globally. 6 Metabolic syndrome is defined as a clustering of risk factors that identify those at increased risk for CVD and diabetes. 8 Differences in the prevalence of metabolic syndrome have been reported in previous studies, and its increased prevalence in patients with diabetes has been recognized. 9Y11 The risk of CVD is greater in patients who have both diabetes and metabolic syndrome than in those with diabetes alone. 12 Glycated hemoglobin (HbA 1c ) values provide one target to lower the risk of CVD in people with diabetes. 13 Glycated hemoglobin has been positively related to CVD risk in patients with diabetes after adjustment for other CVD risk factors. 14 The results of that study suggest that the risk for CVD begins to increase at HbA 1c levels even below 7%. 12, 15 Several CVD risk prediction models and equations have been proposed to calculate 10-year CVD risk for patients with diabetes including the UK Prospective Diabetes Study (UKPDS). 15 The UKPDS risk engine was derived from data of a cohort of patients with diabetes using diabetes-specific variables such as duration of diabetes and HbA 1c , and it is well established as an estimate of CVD risk among patients with diabetes. 16 People with type 2 DM have to adhere to self-care activities such as exercise, diet, and weight control to achieve optimal glycemic control and lower CVD risk. Depression is common in this population and was found to be associated with glycemic control and diabetic complications including CVD risk in previous studies. 17Y22 Persons with diabetes who are depressed have a heightened CVD risk compared with people with diabetes alone. 21, 23 Depression is a common psychological symptom in people with diabetes, affecting about 121 million people worldwide. 24 General population surveys conducted worldwide have revealed a high rate of depression with a lifetime risk of 7% to 12% for men and 20% to 25% for women, 25 which is similar to the prevalence of depression in Korea of 11.7% for men and 15.5% to 21.3% for women reported in one study. 26 People with diabetes experience depression about twice as often as the general population. 27 Previous studies including meta-analyses conducted in various countries have consistently reported a strong association between depression and CVD risk. 28Y30 Greater depressive symptoms were associated with increased all-cause mortality including CVD mortality in the Multiple Risk Factor Intervention Trial cohort study. 31 Depression in people with diabetes may cause poor glycemic control through lower adherence to self-care activities such as exercise and diet control in both Asian 17, 18, 27 and Western countries. 19Y22 In a Korean study of patients with type 2 DM, the levels of cardiovascular risk factors and HbA 1c were significantly higher in the depressed group than those in the nondepressed group, whereas the level of self-care activities was significantly lower in the depressed group. 27 Depression and self-care activities for glycemic control were negatively correlated. 18 So, depression may be attributed to low adherence to self-care activities including exercise and diet control, and this may result in poor glycemic control and high risk of CVD.
17Y19,21
The most widely used method of depression assessment is a self-administrated questionnaire, the Center for Epidemiological StudiesYDepression (CES-D) scale, among patients with type 2 DM. 10, 27, 32 The CES-D is a 20-item questionnaire that assesses depressive symptoms over the previous 7 days. 33 The previous studies suggest that the CES-D reflects general emotional and diabetes-specific affective components of depression, 27, 32 and it was strongly associated with deficits in diabetes-related behavioral and biological variables (ie, physical activity, diet, and HbA 1c , and cholesterol). 32 The primary approach to reducing CVD risk among people with metabolic syndrome/insulin resistance is lifestyle modifications including exercise, weight control, and educational advice about risk factor management. Patients with metabolic syndrome/insulin resistance should be referred to an effective ongoing support program for body weight (loss of 5%Y7% in those who are overweight/obese or weight control in those of normal weight) and increased physical activity to at least 150 minutes of moderate activity each week. 9, 12 One study reported that such a program reduced the risk of diabetes and CVD by 58% in patients with impaired glucose tolerance. 34 Other studies have demonstrated that lifestyle and habitual behavior modifications are essential and effective components for glycemic control and the reduction/ prevention of diabetes-related complications including CVD risk. 35, 36 However, despite the benefits of lifestyle and behavior modification, more than half of those who participated in a behavioral intervention including exercise stopped these activities within 3 to 6 months because the intervention lacked psychobehavioral strategies based on the readiness of individuals to engage in behavioral change. 10, 35, 37 Many behavioral researchers have recommended the Transtheoretical Model (TTM) as a framework for studying how individuals make transitions across the various stages of behavioral change. The TTM focuses on the dynamic nature of moving from an early stage (precontemplation) through further stages (contemplation, preparation, action) to the last stage (maintenance) of health behavior change. 10, 35, 38 Most studies have been conducted in patients with diabetes alone, 35, 36 and only a few studies have examined lifestyle modifications in patients with metabolic syndrome. 39, 40 Also, little research about CVD risk reduction has specifically examined Koreans with either diabetes or metabolic syndrome. In one such study, the authors developed a CVD risk reduction program based on psychobehavioral strategies across the motivational readiness stages of changes (SOCs) for exercise behavior using TTM constructs in 210 Korean adults with metabolic syndrome. 10 The present study evaluated the effects of this CVD risk reduction program among Koran adults with type 2 DM and metabolic syndrome on cardiometabolic risk factors including CVD risk using the UKPDS engine and metabolic risk factors from the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) criteria, SOCs for exercise, glycemic control (HbA 1c ), and depression. The secondary purpose was to examine changes in regular exercise, weight control, and dietary control over a 16-week intervention period.
Hypotheses
The intervention group participating in the 16-week CVD risk reduction program would, compared with the control group, show advanced SOCs for exercise, decreased UKPDS risk, decreased HbA 1c , and decreased depression.
Methods

Research Design
A prospective, pretest and posttest, controlled, quasiexperimental design enrolled a convenience sample of 43 Koran adults with both type 2 DM and metabolic syndrome at a university hospital. Participants were randomly assigned to a CVD risk reduction intervention group or control group and were assessed at baseline and immediately following completion of the 16-week intervention. The independent variable was the CVD risk reduction program, and the dependent variables were SOCs for exercise, HbA 1c , depression, and cardiometabolic risk factors. The risk factors included UKPDS risk, waist circumference, systolic blood pressure (SBP), diastolic blood pressure (DBP), triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), and fasting plasma glucose (FPG). The intervention group participated in the 16-week CVD risk reduction program, whereas the control group received a booklet with basic educational advice on the usual care for diabetes.
Participants and Setting
Forty-three participants with diabetes and metabolic syndrome were recruited from an outpatient diabetic center at a large university hospital in South Korea. They were randomly allocated to the intervention group (n = 21) and control group (n = 22). Metabolic syndrome was defined according to NCEP-ATP III diagnostic criteria. 8 A person with 3 or more of the following inclusion criteria were defined as having metabolic syndrome: abdominal obesity (based on the Korean Society for the Study of Obesity guidelines that are specific to the Korean population) defined as waist circumference of 90 cm or greater in men and 85 cm or greater in women, TG level of 150 mg/dL or greater, HDL-C level of less than 40 mg/dL for men and less than 50 mg/dL for women, and SBP equal to or greater than 130 mm Hg or DBP equal to or greater than 85 mm Hg. Participants who had normal blood analyses or blood pressure values, but reported taking antihypertensive or antidiabetic medication, were classified as having hypertension or diabetes, respectively. Physicians were asked to review the medical records and conditions of all participants and then to refer eligible participants who met the inclusion criteria of the study, which included no change in any medications for the past 3 months. The following exclusion criteria were as follows: contraindications for exercise (screened through interviews by the researcher); uncontrolled chronic complications such as severe retinopathy, nephropathy, or neuropathy; and evidence of heart disease, musculoskeletal disorders, or other disabling diseases that could restrict physical activity training. The sample size was calculated based on a power analysis. A total minimum sample size of 44 was required at an effect size of 0.30, significance of .05, and power of 80% using 2-sided tests. 41 This calculation was based on the effect size derived from a review of previous studies. 35 
Ethical Considerations
Approval was obtained from the institutional review board at the authors' institution (AJIRB-CRO-07-124). Each participant accepted the explanation of the purpose of study and voluntarily signed an informed consent form.
Study Intervention
The CVD risk reduction program protocol was designed for healthcare providers in an outpatient practice to prevent or reduce the CVD risk in Korean adults with type 2 DM and metabolic syndrome on a one-onone basis. Changes in medications and dosages that might have affected the study outcome were not made during the intervention period. The goals for participants in the intervention group were to adopt and maintain 150 minutes of moderate exercise per week and 200-to 300-kcal reduced daily dietary calories for weight control in those with normal weight or for weight loss in overweight or obese patients. The 16-week CVD risk reduction program consisted of 3 components: (a) psychobehavioral strategies using major constructs of the TTM such as processes of change, self-efficacy, and decisional balance based on previous studies in Korean adults with diabetes and/or metabolic syndrome 10, 35, 42 ; (b) the aforementioned weekly exercise and diet, with exercise intensity calculated based on an individualized target heart rate (THR) range obtained from the Heart Rate Reserve method; and (c) telephone counseling for behavioral modification including exercise and diet. The TTM was used to guide the design of psychobehavioral strategies. To determine the appropriate content for the CVD risk reduction intervention, a questionnaire package was distributed to Korean participants with metabolic syndrome 42 to gain data on the following: (a) distribution of SOCs for exercise and weight control including level of knowledge, attitude, intention, and compliance; (b) strategies such as processes of change, self-efficacy, and decisional balance that are often used to correspond with each stage; and (c) any specific difficulties such as symptoms of depression and coping strategies in adopting and maintaining behavior. The content for the psychobehavioral strategies was determined by the results of the questionnaires and findings in the literature.
10,35,42
Psychobehavioral Strategies
Psychobehavioral strategies consisted of preplanned exercise counseling that was individually tailored based on responses of each participant to the questionnaires. 10 A tailored strategy was provided individually to each participant during a 60-to 90-minute initial counseling session and a 30-to 40-minute follow-up counseling session with the researcher on a one-on-one basis during a hospital visit every 2 months. The detailed psychobehavioral strategies are presented in Table 1 . They comprised 2 packages corresponding to the participant's current SOCs and main strategies as they applied to exercise. 10, 42 One package included nonYregular exercise stages or early stages (precontemplation to preparation stages) and consisted of dramatic relief, environmental reevaluation, helping relationships, cons, and self-efficacy. The second package included regular exercise stages or latter stages (action to maintenance stages) and consisted of consciousness raising, self-reevaluation, social liberation, counter conditioning, reinforcement management, self-liberation, stimulus control, pros, and self-efficacy.
Exercise Behavior
All participants were assessed for their present stages of readiness for exercise behavior through the SOCs assessment tool for exercise behavior. The individualized THR range was obtained using the Heart Rate Reserve method. Targets of 150 minutes of moderate exercise weekly (3Y5 exercise periods per week, consisting of 5 minutes of warm-up, 30 minutes of aerobic exercise, and 5 minutes of cool-down) and 200-to 300-kcal reduced daily dietary calories for weight control were established. Exercise was in the form of brisk walking, stair climbing, cycling, climbing, jogging/ running on a treadmill, household tasks, leisurerelated activity, or job-related physical activity. Exercise was low to moderate in intensity, at 40% to 75% of VO 2 max based on results of the THR range and physical condition of each participant. Exercise progression during the 16-week program was adjusted to reflect cardiovascular and muscular adaptations from training. The program leader reassessed and adjusted participant's heart rate responses for at least the first 2 to 3 weeks. Participants in the early stages (precontemplation to preparation stages) or participants who had not previously been regular exercisers performed the moderate activities described by the recent Centers for Disease Control and Prevention/ American College of Sports Medicine recommendations on physical activity. 43 Multiple episodes of moderate-intensity physical activity such as brisk walking could be accumulated in sessions of at least 10 minutes to reach a total of 30 min/d. Participants maintained a weekly exercise and dietary log, indicating the frequency, duration, and kilocalories for energy expenditure by an accelerometer.
Telephone Counseling
One-on-one, 10-to 30-minutes telephone counseling was provided each week by the researcher, who encouraged confidence in the participant regarding being able to continue exercise/physical activity and weight control in a variety of situations. Problems and concerns including depressive symptoms were discussed as part of the CVD risk reduction program. Each participant had been instructed to call the researcher with problems or concerns at any time; during such sessions, the participant and researcher worked together to develop specific and practical problem-solving skills and coping strategies. We focused on the depressive symptoms of participants who had scores of 16 or more as measured by the CES-D scale. 33 
Measurement Tools
Participants were asked to complete a questionnaire that addressed demographics and TTM-related questions. The survey took 25 minutes to complete. Each participant in both groups received a booklet and a measuring tape as an incentive when the questionnaire was returned, whereas an accelerometer was provided to participants in the intervention group. Triglyceride, HDL-C, total cholesterol (TC), FPG, and HbA 1c levels were collected using blood analysis, and blood pressure and waist circumference were manually measured by a research nurse in the outpatient clinic. Demographic variables including sex, age, age at diagnosis of diabetes, current smoking status, education level, and years of diabetes were assessed by a review of medical records, and the questionnaires filled out upon entry into the study. Repeated measures included cardiometabolic risk factors, HbA 1c , and depression. Adherence to the 16-week intervention was measured as changes in regular exercise, weight control, and dietary control over the course of the program.
SOCs for Exercise Behavior
Stages of changes were assessed using the stage of readiness for exercise behavior short-form ordinal scale. 35, 44 45 The . index estimated test-retest reliability for the ordinal scale. The SOCs scale had a substantial . index. 41 
Cardiometabolic Risk Factors and HbA 1c
Fasting plasma glucose and HbA 1c were measured using a Hitachi 747 automatic analyzer (Hitachi, Tokyo, Japan) and NycoCard READER II (Axis-Shield PoC, Oslo, Norway), respectively. Triglyceride, TC, and HDL-C levels were measured using an Olympus Au5200 (Olympus, Tokyo, Japan). Body weight was measured using an Olympia 3.5 Plus apparatus (Jawon Medical, Kyungsan, Korea) at the outpatient clinic by the research nurse, and body mass index (BMI) was calculated by dividing weight (in kilograms) by height (in meters squared). Blood pressure was manually measured using an HM-1101 mercury sphygmomanometer (Hico, Tokyo, Japan), and waist circumference was measured using a measuring tape (Tanita, Tokyo, Japan). Blood pressure measurement followed the American Heart Association guidelines. 46 Specifically, each participant was seated comfortably with back support, an upper arm bared, and the legs uncrossed. The arm was supported at heart level, and the participant was silent during the measurement. Blood pressures were manually measured twice by the trained nurse with a 5-minute rest period, and the average was used to represent the participant's blood pressure. The 10-year absolute CVD risk (in %) was computed using the UKPDS engine version 2.0. 16 The UKPDS defines CVD as the first to occur of myocardial infarction, sudden cardiac death, other incidents of ischemic heart disease, stroke, or peripheral vascular disease death. The variables that go into the UKPDS risk engine are age at diagnosis of diabetes, sex, race, current smoking status, HbA 1c , SBP, and ratio of TC to HDL-C.
Depression
Depression was measured using the CES-D scale. 33 The CES-D scale was developed to assess individual frequency with which each of 20 events was experienced during the past 7 days. The 20-item CES-D consists of major affective components of depression identified in the literature plus positive affect: depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, psychomotor retardation, loss of appetite, sleep disorders, and positive affect. Items were scored using a 4-point Likert scale ranging from Brarely or none of the time[ to Bmost or all of the time.
[ Each subscale uses a 0-to 3-point response scale except for the 4 positive questions, in which a higher score indicates greater depression. To determine a depression score, each of the numbers circled was summed, and the total score ranged from 0 to 60. Scores of 16 or more are commonly taken as indicative of depression. Cronbach ! coefficients of .85 for the general population and of .90 for a patient sample have been reported. 33 Cronbach ! coefficient for this study was .92, indicating acceptable internal consistency.
Statistical Analyses
The SPSS statistical software package version 12.0 for Windows (SPSS, Chicago, Illinois) was used to analyze the data. Descriptive statistics were used to characterize the participants and variables of the study. A # 2 test for categorical variables and a Student t test for continuous variables were used to test baseline equivalence of participants' characteristics and the outcome measurements in the intervention and control groups. The hypotheses were tested using repeated-measures analysis of variance with a between-subjects factor, group, a within-subject factor, time, and the interaction of group by time. Outcome measures were cardiometabolic risk factors, glycemic control, and depression. When a significant difference was found by repeatedmeasures analysis of variance, t tests with a Bonferroni correction were applied to identify specific differences. Statistical significance was accepted for 2-sided P G .05.
Results
Flow of Participants
The flow of participants through the study is shown in the Figure. Of the 1234 Korean adults with diabetes identified, 477 (38.7%) met the NCEP-ATP III eligibility criteria of metabolic syndrome. 8 Of those, 152 expressed an interest in participating and submitted consent forms along with the first survey. Of the 152, 98 were excluded: 66 did not participate in screen tests, 20 refused to participate before the pretest, 5 were in another study, and 7 began new medications. The remaining 54 participants were randomly assigned into the intervention and control groups with 27 participants in each group. During the study, 11 participants (6 and 5 in the intervention and control groups, respectively) withdrew (20.3%). Reasons for withdrawal included personal problems (n = 2), domestic problems (n = 2), aggravated health condition after dental or other treatment (n = 3), nonYexercise-related injury (n = 1), or missed follow-up (n = 3). No differences in attrition were observed between the 2 groups. Forty-three participants were included in the main analysis. The period of recruitment and follow-up was from November 2007 to December 2008.
General Characteristics and Outcomes at Baseline
Demographic characteristics and outcome measurements of the intervention and control groups at baseline are detailed in Table 2 and are briefly summarized here. The mean (SD) age of the participants was 55.6 (10.5) years, and 62.2% of the participants were male. The mean (SD) duration of diabetes was 8.9 (6.4) years. Types of prescriptions included oral hypoglycemic agents (100%), antihypertensive agents (37.8%), lipid-lowering agents (39.4%), and antiplatelet drugs (3.4%). The mean (SD) BMI was 26.4 (4.1) kg/m 2 , indicating that the participants were overweight, and 58% of these participants had a BMI of 25 kg/m 2 or greater. There were no significant differences in outcome measurements including demographic and cardiometabolic risk factors (UKPDS risk, waist circumference, SBP, DBP, TG, HDL-C, and FPG), SOCs for exercise, HbA 1c , and depression at baseline between the 2 groups. Among metabolic risk factors, DBP was the only one within normal limits. The overall average (SD) of CVD risk was 15.3% (8.1%) for men and 10.3% (5.1%) for women (P G .05). The overall averages for TG and HbA 1c were 150 mg/dL and 7%, respectively, higher than the recommended limits of 39.7 mg/dL and 4.1%. The average depression level was 17.3, indicating that these participants had a high rate of depression; 48.8% of the participants had a depression value of 16 or greater.
Hypothesis Testing
The means for cardiometabolic risk factors for the intervention group at baseline and 16 weeks posttest are presented in Table 3 . There was no significant interaction of group by time for any cardiometabolic risk factors. The UKPDS fatal risk for CVD showed borderline significance in the interaction of group by time (F = 3.915, P = .055). Most outcomes showed significant time effects: when the interaction term was removed, fatal CVD risk (F = 4.393, P G .05), SBP (F = 11.166, P G .01), DBP (F = 5.129, P G .05), and TG (F = 8.775, P G .01) decreased in both groups over time. However, there was a significant difference over time (pretest vs posttest) in fatal CVD risk (P G .001), DBP (P G .01), and TG (P G .01) in the intervention group, whereas there was no statistically significant difference in the control group over time. There was a significant group difference in TG (F = 4.633, P G .05). Triglyceride levels showed a significantly greater reduction 
CVD Risk Reduction With Psychobehavioral Strategies 123
in the intervention group (j38.5 mg/dL, P G .01) than in control group (j15.1 mg/dL, P = .104).
The hypotheses testing for effects of the CVD risk reduction intervention on SOCs, glycemic control, and depression at baseline and 16 weeks posttest are presented in Table 4 . There were significant interactions of group by time for SOCs (F = 14.218, P G .001), FPG (F = 9.113, P G .01), HbA 1c (F = 7.127, P G .01), and depression (F = 5.297, P G .05). There were significantly advanced SOCs scores (F = 4.797, P G .05) over time in the intervention group. The intervention group advanced (+0.86), whereas those in the control group did not change significantly. The percentages of participants who progressed, maintained, and regressed from baseline in the intervention group were 57.1%, 42.9%, and 0%, respectively, whereas those for in the control group were 18.2%, 27.3%, and 54.5%, respectively. Fasting plasma glucose did not differ significantly between the 2 groups, but there was a significant decrease in FPG over time (F = 7.148, P G .01). There was a significant mean change (j29.24 mg/dL) in FPG for the intervention group (P G .001), whereas it increased in the control group (+1.77 mg/dL, P = .837). Glycated hemoglobin did not differ significantly between the 2 groups or over time.
However, there was a significant mean decrease in HbA 1c (j0.37%, P G .05) in the intervention group, whereas it increased in the control group (+0.17%, P = .194). Depression did not differ significantly between the 2 groups or over time. However, the average decrease in depression scores for the intervention group (j3.24) was higher than that for the control group (+1.4 score) (P G .05). Changes in Targeted Behavioral Modification after the CVD Risk Reduction Intervention group differences and changes from baseline to posttest in regular exercise, dietary control, and weight control are presented in Table 5 . Regular exercise, frequency, and total duration of exercise and dietary control were monitored using an accelerometer and weekly logs. Participants achieved the exercise and calorie reduction goals. There were no significant differences in regular exercise, dietary control, and weight control between 2 groups at baseline. However, participants in the intervention group showed significant positive changes in regular exercise (P G .001), dietary control (P G .001), and weight control (P G .001), compared with the control group. The percentages of those who successfully completed targeted behavioral modification were 81.0% for exercise, 76.2% for dietary control, and 90.5% for weight control in the intervention group at 16 weeks.
Discussion
To our knowledge, this is the first controlled CVD risk reduction intervention with psychobehavioral strategies based on the TTM for adults with type 2 DM and metabolic syndrome in Korea. This study found that the 16-week CVD risk reduction intervention for Koreans with type 2 DM and metabolic syndrome decreased cardiometabolic risk factors such as TG, 10-year CVD risk, and depression and also improved SOCs scores for exercise and glycemic control. Changes in targeted behavioral modification after CVD risk reduction intervention were relatively high, with 81.0% for exercise, 76.2% for dietary control, and 90.5% for weight control. The results provide evidence for the beneficial impact of the CVD risk reduction intervention with psychobehavioral strategies in participants with type 2 DM and metabolic syndrome. Approximately 39% of Korean adults with diabetes had metabolic syndrome according to the NCEP-ATP III criteria. 8 Metabolic syndrome occurs more frequently in people with diabetes than in the general population. The age-adjusted prevalence of metabolic syndrome among adults 19 years or older was 26.1% in the 2005 Korea National Health and Nutrition Examination Survey using the same criteria. 2 The findings of this study are consistent with those reported in Western countries. 47Y50 Regarding the SOCs for exercise, the present findings are similar to the significant differences in SOCs for exercise that were found between a control group and those who received a TTM-based intervention in a primary care setting. 47,48,50Y52 Approximately 57% of the intervention group progressed, and 43% of them maintained their SOCs from baseline. This result is quite similar to an earlier report that 52% in the intervention group progressed. 50 However, this result was comparable to a previous study where 26% of a work-site health promotion project sample progressed, 15% regressed or relapsed, and 59% maintained. 48 It is important to note that the present study did find that TTM-based approaches also resulted in a shift in stage in a clinical setting.
The beneficial CVD risk reduction found in the present study is consistent with the positive findings of previous studies. Other researchers have reported reduced CVD risks such as decreased single cardiometabolic risk factors or global 10-year CVD risk score in patients with metabolic syndrome and/or diabetes. 36, 39, 40, 53 For TG, Korean adults with diabetes and metabolic syndrome significantly decreased by 38.5 mg/dL following the 16-week intervention, whereas that of the control group decreased by 15.1 mg/dL. However, the level of this in the intervention group decreased to a normal limit with 127.4 mg/dL, whereas that of the control group remained high at 178.5 mg/dL. This finding is consistent with previous life modification studies among Koran adults with metabolic syndrome 39, 40 and those with type 2 DM. 35, 36 Reduced daily dietary calories such as lowcarbohydrate diet and/or weight control may be a contributing factor to this result. In terms of CVD risk, Korean diabetic adults with metabolic syndrome decreased by 1.98% the 10-year CVD risk by UKPDS criteria following the 16-week intervention, whereas those of the control group did not change. Previous determinations of 10-year CVD risk using the UKPDS criteria varied according to diabetes-specific factors including first time duration of diabetes, level of hemoglycated glucose, and age. 53 The average UKPDS-determined 10-year CVD risk was 15.3% in men and 10.3% in women in the present study. This finding indicates that the male participants had borderline risk of CVD, based on the UKPDS indication of elevated risk as values 15% or greater.
Significant improvement in glycemic control was shown in the intervention group as compared with the control group in this study. These findings are consistent with those reported in previous studies among Korean participants with diabetes. 35, 36, 54, 55 Fasting plasma glucose and HbA 1c significantly decreased in Korean adults with type 2 DM and metabolic syndrome after 16 weeks of CVD risk intervention. Glycated hemoglobin decreased by 0.33% in the intervention group, whereas a 0.17% increase was shown in the control group at 16 weeks. These findings are also similar to studies in Western countries of patients with and without metabolic syndrome. 56, 57 The UKPDS showed that each 1% reduction in mean HbA 1c was associated with a 14% to 37% decreased risk for macrovascular and/or microvascular complications. 58 Glycated hemoglobin levels following the 16-week intervention decreased by 7.07% in the current study, indicating a closer-targeted American Diabetes Association value. The HbA 1c goal recommended by the American Diabetes Association and the American College of Endocrinology/American Association of Clinical Endocrinologists for patients in general is less than 6.5% to 7%. 9, 12 Approximately 49% of participants had a depression score of 16 or greater. These findings are inconsistent with findings of previous research conducted in a Korean population with diabetes, 27 which assessed 159 adults with diabetes in a hospital using the same scale as the present study and reported that 44.7% had scores this high. The higher prevalence of depression evident in the current study may have reflected the inclusion only of those with both diabetes and metabolic syndrome. The average depression score of 17.3 in the present study differs from the findings in Korean adults in general 26 or in people with diabetes only. 27 Depression decreased by 3.2 from baseline in the intervention group, whereas a 1.4 increase was shown in the control group following the 16-week intervention.
The depression score at 16 weeks in the intervention group was 13.2, indicating less than the cutoff point (16) of depression criteria. 33 This finding is consistent with previous findings of randomized controlled trials of nonpharmacological treatments such as psychological interventions to reduce depressive symptoms and improve glycemic control in patients with type 2 DM. 59, 60 Meta-analyses have shown that exercise may be efficacious in reducing depressive symptoms. 61, 62 However, a randomized controlled trial with long-term follow-up is needed to evaluate the effectiveness of exercise in reducing depression.
In summary, a 16-week CVD risk reduction intervention showed positive changes in some cardiometabolic risks, glycemic control, and depression for Korean adults with diabetes and metabolic syndrome. The findings suggest that the CVD risk reduction intervention with psychobehavioral strategies could be an effective means of improving glycemic control and continuing follow-up intervention for Koreans with diabetes and metabolic syndrome in any SOCs in a variety of clinical settings. This preliminary study has a limitation stemming from its small sample size and recruitment of participants from a single university hospital. The findings should be confirmed in a study involving a larger and more geographically representative sampling of participants. Further prospective randomized clinical trials with a large sample size are needed to investigate the effect of the CVD risk reduction intervention on the prevention or reduction of CVD risk among this population in clinical and community settings.
Evaluation of depression among patients with type 2 DM in Korea has been overlooked, but the findings of this study showed that at least half of the participants had a high level of depressive symptoms. Regular assessment of lifestyle behavior in addition to depression is needed at the initial healthcare clinic visit among this population. Specially, identifying and managing depressed diabetic patients may help improve their self-care activities such as exercise, diet, and weight control for glycemic control and/or CVD risk in a variety of clinical and community settings. Nurses are at the forefront in increasing public awareness about the association of depression with poor glycemic control and/or CVD risk among those with type 2 DM and metabolic syndrome.
